DK171796B1 - Fremgangsmåde til behandling af et blodstørkningsfaktor VIII koncentrat - Google Patents

Fremgangsmåde til behandling af et blodstørkningsfaktor VIII koncentrat Download PDF

Info

Publication number
DK171796B1
DK171796B1 DK210283A DK210283A DK171796B1 DK 171796 B1 DK171796 B1 DK 171796B1 DK 210283 A DK210283 A DK 210283A DK 210283 A DK210283 A DK 210283A DK 171796 B1 DK171796 B1 DK 171796B1
Authority
DK
Denmark
Prior art keywords
factor viii
blood clotting
clotting factor
virus
concentrate
Prior art date
Application number
DK210283A
Other languages
Danish (da)
English (en)
Other versions
DK210283A (da
DK210283D0 (da
Inventor
Alan Rubenstein
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23490802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK171796(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of DK210283D0 publication Critical patent/DK210283D0/da
Publication of DK210283A publication Critical patent/DK210283A/da
Application granted granted Critical
Publication of DK171796B1 publication Critical patent/DK171796B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2/12—Microwaves
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK210283A 1982-05-13 1983-05-11 Fremgangsmåde til behandling af et blodstørkningsfaktor VIII koncentrat DK171796B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37786382 1982-05-13
US06377863 US4456590B2 (en) 1981-11-02 1982-05-13 Heat treatment of lyphilized blood clotting factor viii concentrate

Publications (3)

Publication Number Publication Date
DK210283D0 DK210283D0 (da) 1983-05-11
DK210283A DK210283A (da) 1983-11-14
DK171796B1 true DK171796B1 (da) 1997-06-02

Family

ID=23490802

Family Applications (1)

Application Number Title Priority Date Filing Date
DK210283A DK171796B1 (da) 1982-05-13 1983-05-11 Fremgangsmåde til behandling af et blodstørkningsfaktor VIII koncentrat

Country Status (19)

Country Link
US (1) US4456590B2 (es)
EP (2) EP0171506B1 (es)
JP (1) JPS58213721A (es)
AR (1) AR230186A1 (es)
AT (1) AT392905B (es)
AU (3) AU554282B2 (es)
BE (1) BE896724A (es)
BR (1) BR8302504A (es)
CA (1) CA1203165A (es)
CH (1) CH665125A5 (es)
DE (3) DE3364057D1 (es)
DK (1) DK171796B1 (es)
ES (5) ES522310A0 (es)
FR (1) FR2526660B1 (es)
GB (2) GB2120254B (es)
IE (1) IE55008B1 (es)
LU (1) LU84804A1 (es)
MX (1) MX172861B (es)
ZA (1) ZA833315B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4994438A (en) * 1981-11-02 1991-02-19 Cedars Sinai Medical Center Heat treatment of lyophilized plasma fractions
DE3230849A1 (de) * 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
CA1207662A (en) * 1982-12-02 1986-07-15 Ricardo H. Landaburu Hepatitis b and non-a-non-b-safe biological products
US4615886A (en) * 1983-08-31 1986-10-07 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT385657B (de) * 1984-03-09 1988-05-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
JPS61501510A (ja) * 1984-03-23 1986-07-24 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテッド ビ−ルスリスクを減らしたヘモグロビンおよびその製造方法
US4831012A (en) * 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
NL8401066A (nl) * 1984-04-04 1985-11-01 Stichting Centraal Lab Werkwijze ter bereiding van preparaten, die de humorale en cellulaire immuunreaktiviteit vergroten.
US5185160A (en) * 1984-06-21 1993-02-09 Prp, Inc. Platelet membrane microvesicles
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
AT390001B (de) * 1984-09-28 1990-03-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
AT390373B (de) * 1984-10-02 1990-04-25 Schwab & Co Gmbh Verfahren zur pasteurisation von plasmaproteinen bzw. von plasmaproteinfraktionen
DE3577801D1 (de) * 1985-08-05 1990-06-28 Immuno Ag Verfahren zur herstellung von praeparationen auf basis von blutgerinnungsfaktoren.
CA1276563C (en) * 1985-09-30 1990-11-20 Stanley E. Charm High temperature, short time heating system and method of sterilizing heat-sensitive biological fluids
EP0225581A3 (en) * 1985-11-30 1989-05-24 Green Cross Corporation Method for the heat-treatment of immunoglobulins and immunoglobulin product
DK595285D0 (da) * 1985-12-20 1985-12-20 Nordisk Gentofte Injicerbart og varmebehandet igg-praeparat og fremgangsmaade til fremstilling af samme
DK155886D0 (da) * 1986-04-04 1986-04-04 Bo Arne Hofmann Vaccine og fremgangsmaade til fremstilling af denne
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
US5118795A (en) * 1987-05-15 1992-06-02 University Of Southern California Sequential heat treatment of blood-clotting factor products
US5097018A (en) * 1988-05-12 1992-03-17 University Of Southern California Sequential heat treatment of blood-clotting factor products
AU2251288A (en) * 1987-05-15 1988-12-06 Alan I. Rubinstein Sequential improved method for treatment of human blood- clotting factor products
US5099002A (en) * 1987-05-15 1992-03-24 University Of Southern California Sequential improved method for treatment of human blood-clotting factor products
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US4861867A (en) * 1988-02-03 1989-08-29 Baxter International, Inc. Purified hemoglobin solutions and method for making same
EP0378208B2 (en) * 1989-01-13 2003-01-15 Mitsubishi Pharma Corporation Production method for protein-containing composition
US5332578A (en) * 1989-04-14 1994-07-26 Prp, Inc. Platelet membrane microparticles
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
JPH06166634A (ja) * 1992-12-01 1994-06-14 Green Cross Corp:The プラスミノーゲン含有組成物の製造方法
JP3133338B2 (ja) * 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4404625C2 (de) * 1994-02-14 1996-10-17 Ludwig Dr Baumgartner Verfahren zur Inaktivierung thermolabiler Viren in biologischem Material unter Beibehaltung der kollagenen Eigenschaften
DE4441167C1 (de) * 1994-11-18 1996-03-14 Fraunhofer Ges Forschung Verfahren zur Trocknung von Blutplasma
US20030143518A1 (en) * 1994-11-18 2003-07-31 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Method of drying blood plasma
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
US5837519A (en) * 1996-11-21 1998-11-17 Bayer Corporation Dry-heat viral inactivation under controlled moisture conditions
DK2193809T3 (en) 1999-02-22 2015-05-26 Univ Connecticut The albumin-free Factor VIII formulation
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
FR2857267B1 (fr) 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
AU2006274835B2 (en) 2005-07-29 2012-05-24 Abbott Laboratories Gmbh Processes for the manufacture of sterilized pancreatin powder
FR2894830B1 (fr) * 2005-12-19 2008-04-04 Lab Francais Du Fractionnement Procede d'inactivation virale par chauffage a sec selon la temperature de transition vitreuse
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
CN111295094A (zh) 2017-10-09 2020-06-16 泰尔茂比司特生物技术有限公司 冻干容器及使用冻干容器的方法
JP2022525742A (ja) 2019-03-14 2022-05-19 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥用ローディングトレイ組立体及びシステム

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100737A (en) * 1958-02-05 1963-08-13 Auerswald Wilhelm Method of preparing a plasma protein solution free of active hepatitis virus and product produced thereby
US3041242A (en) * 1958-06-17 1962-06-26 Sr Courtland H Barr Gas and heat sterilization of dried human plasma
US3859168A (en) * 1967-06-22 1975-01-07 Behringwerke Ag Process of inactivating rabies virus
DE1617350C3 (de) * 1967-06-22 1979-09-06 Behringwerke Ag, 3550 Marburg Verfahren zur Inaktivierung von biologischem Material
US3579631A (en) * 1968-05-21 1971-05-18 Aubrey P Stewart Jr Sterilization of materials containing protein
GB1471336A (en) * 1973-04-16 1977-04-21 Armour Pharma Process for the purification and sterilisation of acidophilic biologicals-
US3998516A (en) * 1973-05-15 1976-12-21 Mabuchi Motor Co. Ltd. Adapter
JPS6015B2 (ja) * 1977-07-16 1985-01-05 株式会社新潟鐵工所 水溶性かつ熱凝固性を有する殺菌された血粉の製造方法
US4250139A (en) * 1979-02-01 1981-02-10 Collagen Corporation Microwave sterilization of dry protein
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate

Also Published As

Publication number Publication date
CH665125A5 (de) 1988-04-29
ES8601701A1 (es) 1985-11-01
ES8501627A1 (es) 1984-12-01
ES538802A0 (es) 1985-11-01
GB2120254B (en) 1984-06-20
DE3364057D1 (en) 1986-07-17
DK210283A (da) 1983-11-14
GB2120254A (en) 1983-11-30
AR230186A1 (es) 1984-03-01
EP0094611B1 (en) 1986-06-11
EP0171506B1 (en) 1993-09-22
AU569428B2 (en) 1988-01-28
BR8302504A (pt) 1983-10-25
CA1203165A (en) 1986-04-15
IE55008B1 (en) 1990-04-25
ES8601700A1 (es) 1985-11-01
EP0094611A3 (en) 1984-08-22
AU5765986A (en) 1986-10-09
ZA833315B (en) 1984-01-25
US4456590A (en) 1984-06-26
DE3382716T2 (de) 1994-03-31
IE831068L (en) 1983-11-13
GB8332374D0 (en) 1984-01-11
GB2144428B (en) 1986-03-12
BE896724A (fr) 1983-09-01
DK210283D0 (da) 1983-05-11
GB8312915D0 (en) 1983-06-15
ES535745A0 (es) 1985-06-16
US4456590B2 (en) 1989-05-30
AU568979B2 (en) 1988-01-14
EP0094611A2 (en) 1983-11-23
LU84804A1 (fr) 1983-11-17
AU554282B2 (en) 1986-08-14
DE3382716D1 (de) 1993-10-28
ATA176783A (de) 1985-10-15
AU1442183A (en) 1983-12-15
AU5766086A (en) 1986-10-30
ES538801A0 (es) 1985-11-01
AT392905B (de) 1991-07-10
MX172861B (es) 1994-01-17
GB2144428A (en) 1985-03-06
ES8505821A1 (es) 1985-06-16
ES522310A0 (es) 1984-12-01
ES538803A0 (es) 1985-11-01
ES8601699A1 (es) 1985-11-01
FR2526660B1 (fr) 1987-11-20
US4456590B1 (es) 1989-01-03
JPS58213721A (ja) 1983-12-12
DE171506T1 (de) 1986-11-06
FR2526660A1 (fr) 1983-11-18
EP0171506A1 (en) 1986-02-19

Similar Documents

Publication Publication Date Title
DK171796B1 (da) Fremgangsmåde til behandling af et blodstørkningsfaktor VIII koncentrat
JP3512163B2 (ja) ウイルス不活化能の決定法
CA1223203A (en) Protein compositions substantially free from infectious agents
Edwards et al. Tri (n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives
JP4841018B2 (ja) 生物学的製品の最終滅菌法
JPS6051116A (ja) 脂質含有ウイルスを含まない蛋白質含有組成物及びその製造方法
US5639730A (en) Method of producing a virus-safe biological preparation
US4490361A (en) Virus inactivating heat treatment of plasma fractions
JPH0611702B2 (ja) 治療上活性な蛋白質組成物の熱処理方法
Hart et al. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates
JP2879427B2 (ja) ウイルスおよびバクテリア汚染物の熱的不活性化中の生物学的および製薬的生成物の安定化
WO1998030230A1 (fr) Compositions proteinees et procede de production
US4556558A (en) Treatment of factor VIII concentrate to minimize the affect of undesirable microorganisms
JP4629831B2 (ja) ウィルスの不活化方法
US4994438A (en) Heat treatment of lyophilized plasma fractions
US4845074A (en) Heat treatment of Factor VIII
Mannucci Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B
Schramm Haemate® P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience
IE55182B1 (en) Heat treatment of plasma
KR960015104B1 (ko) 화학적으로 변형되지 않은 γ-글로부린을 열처리하는 방법
Gerety Prevention of transmission of virus infections by blood transfusions and removal of virus infectivity from clotting factor concentrates
KR100276155B1 (ko) 화학적으로 변형되지 않은 γ-글로불린 제제
Mozen HIV inactivation in plasma products
JPS58205495A (ja) 胎盤性アスパラギン酸アミノペプチダ−ゼの加熱安定化法
HUT70476A (en) Process for defining virus-inactivating capacity

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired